Peptide fact-sheets.
Translated adaptations of the canonical pephealth Portuguese fact-sheets. Each one carries mechanism, pivotal RCTs with PMIDs and NCT IDs, pharmacokinetics, safety profile and the international regulatory frame — FDA, EMA, WHO INN, WADA when relevant. For ANVISA-specific regulatory detail and dosing forms registered in Brazil, see the Portuguese fact-sheet linked at the bottom of each page.
BPC-157
Synthetic pentadecapeptide (gastric juice-derived, Body Protection Compound)
Pentadecapeptide derived from human gastric juice; preclinical evidence only, no regulatory approval, WADA-prohibited.
Last reviewed: 2026-05-24 · Source (pt-BR): /peptideos/bpc-157
CJC-1295
Synthetic GHRH analog (long-acting via albumin conjugation in the DAC variant)
Long-acting GHRH analog with two variants (DAC and Mod-GRF 1-29); investigational, no regulatory approval, WADA-prohibited.
Last reviewed: 2026-05-24 · Source (pt-BR): /peptideos/cjc-1295
Retatrutide
Triple GIP, GLP-1, and glucagon receptor agonist
Triple GIP/GLP-1/glucagon receptor agonist in phase 3; mean weight loss 24.2% at 48 weeks in phase 2.
Last reviewed: 2026-05-24 · Source (pt-BR): /peptideos/retatrutida
Semaglutide
GLP-1 receptor agonist
Once-weekly GLP-1 receptor agonist with phase 3 evidence in type 2 diabetes, obesity, and cardiovascular outcomes.
Last reviewed: 2026-05-24 · Source (pt-BR): /peptideos/semaglutida
Tirzepatide
Dual GIP and GLP-1 receptor agonist
First dual GIP/GLP-1 receptor agonist with superior weight loss vs semaglutide in the SURMOUNT-5 head-to-head.
Last reviewed: 2026-05-24 · Source (pt-BR): /peptideos/tirzepatida